Publications

Export 74 results:
Auteur Title [ Type(Desc)] Année
Filtres: Auteur is Serge Gauthier  [Enlever les filtres]
Journal Article
Gauthier S, Schlaefke S.  2014.  Efficacy and tolerability of Ginkgo biloba extract EGb 761® in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials.. Clin Interv Aging. 9:2065-77.
Benedet AL, Labbe A, Lemay P, Zimmer ER, Pascoal TA, Leuzy A, Mathotaarachchi S, Mohades S, Shin M, Dionne-Laporte A et al..  2015.  Epistasis analysis links immune cascades and cerebral amyloidosis.. J Neuroinflammation. 12:227.
Gauthier S, Rosa-Neto P, Kass JS.  2016.  Ethical Considerations for the Use of Next-Generation Alzheimer Drugs in Symptomatic and At-Risk Patients.. Continuum (Minneap Minn). 22(2 Dementia):615-8.
Vellas B., Sampaio C., Bateman R., Boxer A., Carrillo MC., Cummings J., Dubois B., Hampel H., Katz R., Khachaturian Z. et al..  2014.  E.U./U.S. CTAD Task Force on Alzheimer's Trial Populations. J Prev Alz Dis. 1:110-116.
Schoemaker D, Poirier J, D Collins L, Gauthier S, Pruessner JC.  2017.  Familiarity deficits in cognitively normal aging individuals with APOE ε4: A follow-up investigation of medial temporal lobe structural correlates.. Alzheimers Dement (Amst). 9:21-24.
Maria Rajah N, Wallace LMK, Ankudowich E, Yu EH, Swierkot A, Patel R, M Chakravarty M, Naumova D, Pruessner J, Joober R et al..  2017.  Family history and APOE4 risk for Alzheimer's disease impact the neural correlates of episodic memory by early midlife.. Neuroimage Clin. 14:760-774.
Wimo A, Ballard C, Brayne C, Gauthier S, Handels R, Jones RW, Jonsson L, Khachaturian AS, Kramberger M.  2014.  Health economic evaluation of treatments for Alzheimer's disease: impact of new diagnostic criteria.. J Intern Med. 275(3):304-16.
Schoemaker D, Buss C, Head K, Sandman CA, Davis EP, M Chakravarty M, Gauthier S, Pruessner JC.  2016.  Hippocampus and amygdala volumes from magnetic resonance images in children: Assessing accuracy of FreeSurfer and FSL against manual segmentation.. Neuroimage. 129:1-14.
Gauthier S, Leuzy A, Rosa-Neto P.  2014.  How can we improve transfer of outcomes from randomized clinical trials to clinical practice with disease-modifying drugs in Alzheimer's disease? Neurodegener Dis. 13(2-3):197-9.
Mathotaarachchi S, Pascoal TA, Shin M, Benedet AL, Kang MSu, Beaudry T, Fonov VS, Gauthier S, Rosa-Neto P.  2017.  Identifying incipient dementia individuals using machine learning and amyloid imaging.. Neurobiol Aging. 59:80-90.
Leuzy A, Zimmer ERigon, Bhat V, Rosa-Neto P, Gauthier S.  2014.  Imaging biomarkers for amyloid: a new generation of probes and what lies ahead.. Int Psychogeriatr. 26(5):703-7.
Zimmer ER, Parent MJ, Leuzy A, Aliaga A, Aliaga A, Moquin L, Schirrmacher ES, Soucy J-P, Skelin I, Gratton A et al..  2015.  Imaging in vivo glutamate fluctuations with [(11)C]ABP688: a GLT-1 challenge with ceftriaxone.. J Cereb Blood Flow Metab. 35(7):1169-74.
Leuzy A, Zimmer ERigon, Dubois J, Pruessner J, Cooperman C, Soucy J-P, Kostikov A, Schirmaccher E, Désautels R, Gauthier S et al..  2015.  In vivo characterization of metabotropic glutamate receptor type 5 abnormalities in behavioral variant FTD.. Brain Struct Funct.
Pascoal TA, Shin M, Kang MSu, Chamoun M, Chartrand D, Mathotaarachchi S, Bennacef I, Therriault J, Ng KPin, Hopewell R et al..  2018.  In vivo quantification of neurofibrillary tangles with [F]MK-6240.. Alzheimers Res Ther. 10(1):74.
Zimmer ERigon, Leuzy A, Bhat V, Gauthier S, Rosa-Neto P.  2014.  In vivo tracking of tau pathology using positron emission tomography (PET) molecular imaging in small animals.. Transl Neurodegener. 3(1):6.
Bier N, Grenier S, Brodeur C, Gauthier S, Gilbert B, Hudon C, Lepage E, Ouellet M-C, Viscogliosi C, Belleville S.  2015.  Measuring the impact of cognitive and psychosocial interventions in persons with mild cognitive impairment with a randomized single-blind controlled trial: rationale and design of the MEMO+ study.. Int Psychogeriatr. 27(3):511-25.
Zimmer ER, Parent MJ, A Cuello C, Gauthier S, Rosa-Neto P.  2014.  MicroPET imaging and transgenic models: a blueprint for Alzheimer's disease clinical research.. Trends Neurosci. 37(11):629-41.
Ismail Z, Agüera-Ortiz L, Brodaty H, Cieslak A, Cummings J, Fischer CE, Gauthier S, Geda YE, Herrmann N, Kanji J et al..  2017.  The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations.. J Alzheimers Dis. 56(3):929-938.
Petersen RC, Caracciolo B, Brayne C, Gauthier S, Jelic V, Fratiglioni L.  2014.  Mild cognitive impairment: a concept in evolution.. J Intern Med. 275(3):214-28.
Ng KPin, Pascoal TA, Mathotaarachchi S, Therriault J, Kang MSu, Shin M, Guiot M-C, Guo Q, Harada R, Comley RA et al..  2017.  Monoamine oxidase B inhibitor, selegiline, reduces (18)F-THK5351 uptake in the human brain.. Alzheimers Res Ther. 9(1):25.
Bergeron D, Flynn K, Verret L, Poulin S, Bouchard RW, Bocti C, Fülöp T, Lacombe G, Gauthier S, Nasreddine Z et al..  2017.  Multicenter Validation of an MMSE-MoCA Conversion Table.. J Am Geriatr Soc. 65(5):1067-1072.
Parent MJ, Zimmer ER, Shin M, Kang MSu, Fonov VS, Mathieu A, Aliaga A, Kostikov A, Carmo SDo, Dea D et al..  2017.  Multimodal Imaging in Rat Model Recapitulates Alzheimer's Disease Biomarkers Abnormalities.. J Neurosci. 37(50):12263-12271.
Ng KPin, Pascoal TA, Mathotaarachchi S, Chung C-O, Benedet AL, Shin M, Kang MSu, Li X, Ba M, Kandiah N et al..  2017.  Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.. Neurology. 88(19):1814-1821.
Gauthier S, Herrmann N, Rosa-Neto P.  2018.  Optimal use of cholinergic drugs in Alzheimer's disease.. Brain.
Cloutier S, Chertkow H, Kergoat M-J, Gauthier S, Belleville S.  2015.  Patterns of Cognitive Decline Prior to Dementia in Persons with Mild Cognitive Impairment.. J Alzheimers Dis. 47(4):901-13.

Pages


  • Douglas Hospital
  • Dobell Pavillion
  • Brain imaging centre